Literature DB >> 15497686

Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a.

Thomas E Tarara1, Michael S Hartman, Howard Gill, Alan A Kennedy, Jeffry G Weers.   

Abstract

PURPOSE: To assess the physicochemical characteristics and aerosol properties of suspensions of lipid-coated budesonide microcrystals dispersed in HFA-134a.
METHODS: Lipid-coated budesonide microcrystals were prepared by spray-drying an emulsion-based feedstock. Physicochemical characteristics of spray-dried particles were assessed by electron microscopy, laser diffraction, and differential scanning calorimetry. Purity and content were determined by reverse-phase HPLC. Particle aggregation and suspension stability were assessed visually, and aerosol performance was assessed by Andersen cascade impaction and dose content uniformity.
RESULTS: Spray-drying of micronized budesonide microcrystals in the presence of phospholipid-coated emulsion droplets results in the production of low-density lipid-coated microcrystals with low surface energy. These spray-dried particles form stable suspensions in HFA-134a. This translates into good uniformity in the metered dose across the contents of the inhaler and acceptable aerodynamic particle size distributions (MMAD = 3.2 to 3.4 microm). The formulation was observed to maintain its performance over 6 months at 40 degrees C/75% RH and 16 months at 25 degrees C/60% RH. No effect of storage orientation was observed on the content of first sprays following storage (i.e., no Cyr effect). The fine particle dose was found to be linear out to suspension concentrations of about 2% wt/vol, and FPD(4.7 microm) values approaching 400 microg can be delivered in a single inhalation.
CONCLUSIONS: Engineered particles comprised of lipid-coated microcrystals may provide an acceptable alternative formulation technology for metered dose inhalers in the new hydrofluoroalkane propellants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15497686     DOI: 10.1023/b:pham.0000041455.13980.f1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Hollow porous particles in metered dose inhalers.

Authors:  L A Dellamary; T E Tarara; D J Smith; C H Woelk; A Adractas; M L Costello; H Gill; J G Weers
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

2.  How well do in vitro particle size measurements predict drug delivery in vivo?

Authors:  S P Newman
Journal:  J Aerosol Med       Date:  1998

Review 3.  Distal lung inflammation in asthma.

Authors:  E Rand Sutherland; Richard J Martin
Journal:  Ann Allergy Asthma Immunol       Date:  2002-08       Impact factor: 6.347

4.  Influence of the storage orientation on the aerodynamic particle size of a suspension metered dose inhaler containing propellant HFA-227.

Authors:  Julianne Berry; Lukeysha C Kline; John L Hart; Joel Sequeira
Journal:  Drug Dev Ind Pharm       Date:  2003-07       Impact factor: 3.225

5.  Determination of drug solubility in aerosol propellants.

Authors:  R N Dalby; E M Phillips; P R Byron
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

6.  Low first-spray drug content in albuterol metered-dose inhalers.

Authors:  T D Cyr; S J Graham; K Y Li; E G Lovering
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

Review 7.  Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system.

Authors:  D L Ross; B J Gabrio
Journal:  J Aerosol Med       Date:  1999

8.  Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures.

Authors:  B C Hancock; S L Shamblin; G Zografi
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

9.  Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model.

Authors:  Hettie M Janssens; Johan C De Jongste; Wim C J Hop; Harm A W M Tiddens
Journal:  Chest       Date:  2003-06       Impact factor: 9.410

10.  Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder.

Authors:  Sarma P Duddu; Steven A Sisk; Yulia H Walter; Thomas E Tarara; Kevin R Trimble; Andrew R Clark; Michael A Eldon; Rebecca C Elton; Matthew Pickford; Peter H Hirst; Stephen P Newman; Jeffry G Weers
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

View more
  11 in total

Review 1.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

2.  Anomalous particle size shift during post-milling storage.

Authors:  Wai Kiong Ng; Jin Wang Kwek; Reginald B H Tan
Journal:  Pharm Res       Date:  2007-11-29       Impact factor: 4.200

Review 3.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

Review 4.  Advances in metered dose inhaler technology: formulation development.

Authors:  Paul B Myrdal; Poonam Sheth; Stephen W Stein
Journal:  AAPS PharmSciTech       Date:  2014-01-23       Impact factor: 3.246

5.  NanoXCT: a novel technique to probe the internal architecture of pharmaceutical particles.

Authors:  Jennifer Wong; Dexter D'Sa; Matthew Foley; John Gar Yan Chan; Hak-Kim Chan
Journal:  Pharm Res       Date:  2014-05-28       Impact factor: 4.200

Review 6.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Authors:  David E Geller; Jeffry Weers; Silvia Heuerding
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-11       Impact factor: 2.849

7.  Spray Dried Rugose Lipid Particle Platform for Respiratory Drug Delivery.

Authors:  Hui Wang; Mani Ordoubadi; Patrick Connaughton; Kellisa Lachacz; Nicholas Carrigy; Scott Tavernini; Andrew R Martin; Warren H Finlay; David Lechuga-Ballesteros; Reinhard Vehring
Journal:  Pharm Res       Date:  2022-04-01       Impact factor: 4.200

8.  Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants.

Authors:  Libo Wu; Balaji Bharatwaj; Jayanth Panyam; Sandro R P da Rocha
Journal:  Pharm Res       Date:  2007-10-17       Impact factor: 4.200

9.  Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals.

Authors:  Darragh Murnane; Gary P Martin; Christopher Marriott
Journal:  Pharm Res       Date:  2008-05-29       Impact factor: 4.200

10.  Isothermal microcalorimetry of pressurized systems II: effect of excipient and water ingress on formulation stability of amorphous glycopyrrolate.

Authors:  Dexter J D'Sa; David Lechuga-Ballesteros; Hak-Kim Chan
Journal:  Pharm Res       Date:  2014-09-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.